OBJECTIVES: Minoxidil, is proven to be effective in the treatment of alopecia. As Minoxidil and diazoxide, which are potassium channel openers have been used in severe hypertension. The commonest side effect of diazoxide is hyperglycemia, due to opening of potassium channel in beta cells producing hyperpolarisation that inhibits insulin release. So when concomitantly K+ channel activators are used, they may oppose the actions of commonly used sulfonylureas in type2 Diabetics with hypertension. There is paucity of literature in pre–clinical studies regarding the consequences of pharmacodynamic drug interaction between the two drugs and non–diabetic and diabetic persons on blood glucose levels. To evaluate the effect of Minoxidil on euglycemic and type2 diabetic and its interaction with glibencalamide, in type2 diabetic animal models. METHODS: Type2 diabetes was induced by High fat diet–fed and low dose streptozotocin 35mg/kg i.p. Rats with blood glucose level between 250–350mg% were considered and divided into various groups according to protocol. RESULTS: In 28 days treatment with Minoxidil (500µ/Kg,oral) produced euglycemia in non–diabetic rats, hyperglycemia in diabetic rats and antagonised the effect of glibenclamide in diabetic rats. CONCLUSION: These results indicate that Minoxidil has hyperglycemic effect in diabetic rats, euglycemic effect in non–diabetic rats and it reduced the hypoglycemic effect of glibenclamide when it is used in type2 diabetic models of rats